» Articles » PMID: 29138295

Generation of Specific Inhibitors of SUMO-1- and SUMO-2/3-mediated Protein-protein Interactions Using Affimer (Adhiron) Technology

Abstract

Because protein-protein interactions underpin most biological processes, developing tools that target them to understand their function or to inform the development of therapeutics is an important task. SUMOylation is the posttranslational covalent attachment of proteins in the SUMO family (SUMO-1, SUMO-2, or SUMO-3), and it regulates numerous cellular pathways. SUMOylated proteins are recognized by proteins with SUMO-interaction motifs (SIMs) that facilitate noncovalent interactions with SUMO. We describe the use of the Affimer system of peptide display for the rapid isolation of synthetic binding proteins that inhibit SUMO-dependent protein-protein interactions mediated by SIMs both in vitro and in cells. Crucially, these synthetic proteins did not prevent SUMO conjugation either in vitro or in cell-based systems, enabling the specific analysis of SUMO-mediated protein-protein interactions. Furthermore, through structural analysis and molecular modeling, we explored the molecular mechanisms that may underlie their specificity in interfering with either SUMO-1-mediated interactions or interactions mediated by either SUMO-2 or SUMO-3. Not only will these reagents enable investigation of the biological roles of SUMOylation, but the Affimer technology used to generate these synthetic binding proteins could also be exploited to design or validate reagents or therapeutics that target other protein-protein interactions.

Citing Articles

SUMO2/3 conjugation of TDP-43 protects against aggregation.

Verde E, Antoniani F, Mediani L, Secco V, Crotti S, Ferrara M Sci Adv. 2025; 11(8):eadq2475.

PMID: 39982984 PMC: 11844728. DOI: 10.1126/sciadv.adq2475.


Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis.

Pechlivani N, Alsayejh B, Almutairi M, Simmons K, Gaule T, Phoenix F Blood Adv. 2024; 9(1):89-100.

PMID: 39504559 PMC: 11742610. DOI: 10.1182/bloodadvances.2024014235.


Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer.

Xu R, Tiede C, Calabrese A, Cheah L, Adams T, Gauer J Blood Adv. 2024; 8(15):3917-3928.

PMID: 38838227 PMC: 11321386. DOI: 10.1182/bloodadvances.2024012689.


Interplay between PML NBs and HIRA for H3.3 dynamics following type I interferon stimulus.

Kleijwegt C, Bressac F, Seurre C, Bouchereau W, Cohen C, Texier P Elife. 2023; 12.

PMID: 37227756 PMC: 10212570. DOI: 10.7554/eLife.80156.


MD Simulation Reveals Regulation of Mechanical Force and Extracellular Domain 2 on Binding of DNAM-1 to CD155.

Fang L, Zhao Y, Guo P, Fang Y, Wu J Molecules. 2023; 28(6).

PMID: 36985819 PMC: 10053669. DOI: 10.3390/molecules28062847.


References
1.
Shih H, Chang C, Kuo H, Lin D . Daxx mediates SUMO-dependent transcriptional control and subnuclear compartmentalization. Biochem Soc Trans. 2007; 35(Pt 6):1397-400. DOI: 10.1042/BST0351397. View

2.
Hughes D, Wood J, Jackson B, Baquero-Perez B, Whitehouse A . NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target. PLoS Pathog. 2015; 11(3):e1004771. PMC: 4368050. DOI: 10.1371/journal.ppat.1004771. View

3.
Namanja A, Li Y, Su Y, Wong S, Lu J, Colson L . Insights into high affinity small ubiquitin-like modifier (SUMO) recognition by SUMO-interacting motifs (SIMs) revealed by a combination of NMR and peptide array analysis. J Biol Chem. 2011; 287(5):3231-40. PMC: 3270977. DOI: 10.1074/jbc.M111.293118. View

4.
Emsley P, Lohkamp B, Scott W, Cowtan K . Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 4):486-501. PMC: 2852313. DOI: 10.1107/S0907444910007493. View

5.
Berndt A, Wilkinson K, Heimann M, Bishop P, Henley J . In vivo characterization of the properties of SUMO1-specific monobodies. Biochem J. 2013; 456(3):385-95. DOI: 10.1042/BJ20130241. View